Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-m42fx Total loading time: 0 Render date: 2024-07-23T13:29:15.499Z Has data issue: false hasContentIssue false

Vigabatrin

Published online by Cambridge University Press:  01 June 2018

Philip N. Patsalos  and
Erik K. St Louis
Philip N. Patsalos
Affiliation:
UCL Institute for Neurology
Erik K. St Louis
Affiliation:
Mayo Clinic
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Epilepsy Prescriber's Guide to Antiepileptic Drugs , pp. 329 - 338
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Conway, M, Cubbidge, RP, Hoskings, SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49: 108–116.CrossRefGoogle ScholarPubMed
Friedman, D, Bogner, M, Parker-Menzer, K, Devinsky, O. Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. Epilepsy and Behavior 2013; 27: 118–120.CrossRefGoogle ScholarPubMed
Go, CY, Mackay, MT, Weiss, SK, Stephens, D, Adams-Webber, T, Ashwal, S, Snead, OC 3rd; Child Neurology Society; American Academy of Neurology. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78: 1974–1980.CrossRefGoogle Scholar
Johannessen Landmark, C, Patsalos, PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140.CrossRefGoogle ScholarPubMed
Moskowitz, A, Hansen, RM, Eklund, SE, Fulton, AB. Electroretino-graphic (ERG) responses in pediatric patients using vigabatrin. Doc Ophthalmology 2012; 124: 197–209.CrossRefGoogle Scholar
Patsalos, PN. Antiepileptic drug interactions: a clinical guide, 3rd edition. Springer, London, UK; 2016.CrossRefGoogle Scholar
Patsalos, PN, Duncan, J S. The pharmacology and pharmacokinetics of vigabatrin. Reviews in Contemporary Pharmacotherapy 1995; 6: 447–456.Google Scholar
Ryan, MF, Samy, A, Young, J. Vigabatrin causes profound reduction in serum alanine transferase activity. Annals of Clinical Biochemistry 1996; 33: 257–258.CrossRefGoogle Scholar
Shields, WD. Infantile spasms: little seizures, big consequences. Epilepsy Currents 2006; 6:63–69.CrossRefGoogle ScholarPubMed
Sills, GJ, Patsalos, PN, Butler, E, Forrest, G, Ratnaraj, N, Brodie, MJ. Visual field constrictions. Accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196–200.CrossRefGoogle Scholar
Wheless, JW, Carmant, L, Bebin, M, Conry, JA, Chiron, C, Elterman, RD, Frost, M, Paolicchi, JM, Donald Shields, W, Thiele, EA, Zupanc, ML, Collins, SD. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50: 195–205.CrossRefGoogle ScholarPubMed
Wheless, JW, Clarke, DF, Arzimanoglou, A, Carpenter, D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disorders 2007; 9: 353–412.Google ScholarPubMed
Wheless, JW, Ramsey, RE, Collins, SD. Vigabatrin. Neurotherapeutics 2007; 4: 163–172.CrossRefGoogle ScholarPubMed
Willmore, LJ, Abelson, MB, Ben-Menachem, E, Pellock, JM, Shields, WD. Vigabatrin: 2008 update. Epilepsia 2009; 50: 163–173.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×